2月4日 - ** 美国药品分销商 McKesson MCK.N股价盘后上涨 2%，报 837.96 美元
** MCK上调 (link) 年度利润预期，看好肿瘤学和特药分销业务的强劲增长。
** 预计年度调整后每股收益介于 38.80 美元至 39.20 美元之间，此前预期为 38.35 美元至 38.85 美元。
** 公布第三季度营收为1,061.6亿美元，预期为1,058.6亿美元——数据由LSEG编译
** 季度调整后每股收益为 9.34 美元，超过分析师预期的 9.22 美元
** 2025 年股价上涨 43%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.